Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 18/20 | 0.51 |
| ▸ | MTOR | P42345 | 12/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.50 |
| ▸ | ATR | Q13535 | 6/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067589 | 0.91 | MTOR (0.57) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL2067671 | 0.90 | MTOR (0.51) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL2068027 | 0.88 | ATM (0.67) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL2068796 | 0.88 | ATM (0.51) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL2067421 | 0.85 | ATM (0.52) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL2068175 | 0.85 | MTOR (0.51) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL2069276 | 0.84 | MTOR (0.53) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL2069423 | 0.84 | MTOR (0.55) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL2067412 | 0.84 | MTOR (0.52) | ATMMTORPIK3CAATRPIK3CD | |
| SCHEMBL2068324 | 0.83 | MTOR (0.60) | ATMMTORPIK3CAATRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | claimed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | claimed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | claimed |
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | ATM 1084/4885MTOR 326/4885PIK3CA 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.